Thyme Care was spotlighted in Bloomberg after closing a $97 million Series D round that pushes its valuation past $1 billion. The coverage emphasizes the company’s ambition to improve cancer care delivery by leveraging AI-driven, clinically integrated care to enhance cancer treatment experiences. This milestone signals robust investor confidence and fuels our plans for deeper expansion, tech development, and scaling across markets. Preview below:
Thyme Care Inc., a startup that aims to improve the patient experience for people in cancer treatment, has raised $97 million in a new round of venture capital funding, executives told Bloomberg News.
The latest deal values the Nashville-based company at $1 billion, according to people familiar with the matter who asked not to be named discussing private information. It was reported to be valued at $480 million in its previous funding round last year.
About 2 million Americans are diagnosed with cancer each year, according to the National Cancer Institute. The fragmented US health-care system can make the diagnosis harder: Clinics have long wait times. Different doctors, labs and imaging centers don’t always talk to one another or relay information smoothly. Patients can have trouble getting people on the phone and sometimes have to make choices about tests and treatments with incomplete information.
“When you’re told that you might have cancer, it’s really tough to navigate through the system,” said Robin Shah, chief executive and co-founder of Thyme Care, in an interview.